BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34765312)

  • 1. The transcription co-factor JAB1/COPS5, serves as a potential oncogenic hub of human chondrosarcoma cells
    Mamidi MK; Samsa WE; Danielpour D; Chan R; Zhou G
    Am J Cancer Res; 2021; 11(10):5063-5075. PubMed ID: 34765312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The transcriptional cofactor Jab1/Cops5 is crucial for BMP-mediated mouse chondrocyte differentiation by repressing p53 activity.
    Mamidi MK; Samsa WE; Bashur LA; Chen Y; Chan R; Lee B; Zhou G
    J Cell Physiol; 2021 Aug; 236(8):5686-5697. PubMed ID: 33393086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The transcriptional co-regulator Jab1 is crucial for chondrocyte differentiation in vivo.
    Chen D; Bashur LA; Liang B; Panattoni M; Tamai K; Pardi R; Zhou G
    J Cell Sci; 2013 Jan; 126(Pt 1):234-43. PubMed ID: 23203803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The master developmental regulator Jab1/Cops5/Csn5 is essential for proper bone growth and survival in mice.
    Samsa WE; Mamidi MK; Hausman BS; Bashur LA; Greenfield EM; Zhou G
    Bone; 2021 Feb; 143():115733. PubMed ID: 33157284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The crucial p53-dependent oncogenic role of JAB1 in osteosarcoma in vivo.
    Samsa WE; Mamidi MK; Bashur LA; Elliott R; Miron A; Chen Y; Lee B; Greenfield EM; Chan R; Danielpour D; Zhou G
    Oncogene; 2020 Jun; 39(23):4581-4591. PubMed ID: 32390003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stat3 and CCAAT/enhancer binding protein beta (C/EBP-beta) regulate Jab1/CSN5 expression in mammary carcinoma cells.
    Shackleford TJ; Zhang Q; Tian L; Vu TT; Korapati AL; Baumgartner AM; Le XF; Liao WS; Claret FX
    Breast Cancer Res; 2011 Jun; 13(3):R65. PubMed ID: 21689417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Jab1/COPS5 as a Novel Biomarker for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Human Cancer.
    Liu G; Claret FX; Zhou F; Pan Y
    Front Pharmacol; 2018; 9():135. PubMed ID: 29535627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Jab1/Csn5-Thioredoxin Signaling in Relapsed Acute Monocytic Leukemia under Oxidative Stress.
    Zhou F; Pan Y; Wei Y; Zhang R; Bai G; Shen Q; Meng S; Le XF; Andreeff M; Claret FX
    Clin Cancer Res; 2017 Aug; 23(15):4450-4461. PubMed ID: 28270496
    [No Abstract]   [Full Text] [Related]  

  • 9. The emerging roles of Jab1/CSN5 in cancer.
    Wang L; Zheng JN; Pei DS
    Med Oncol; 2016 Aug; 33(8):90. PubMed ID: 27412572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSN5/JAB1 suppresses the WNT inhibitor DKK1 in colorectal cancer cells.
    Jumpertz S; Hennes T; Asare Y; Schütz AK; Bernhagen J
    Cell Signal; 2017 Jun; 34():38-46. PubMed ID: 28229932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of jab1 in osteochondral progenitor cells severely impairs embryonic limb development in mice.
    Bashur LA; Chen D; Chen Z; Liang B; Pardi R; Murakami S; Zhou G
    J Cell Physiol; 2014 Nov; 229(11):1607-17. PubMed ID: 24604556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel Jab1 inhibitor CSN5i-3 suppresses cell proliferation and induces apoptosis in human breast cancer cells.
    Xiao H; Claret FX; Shen Q
    Neoplasma; 2019 May; 66(3):481-486. PubMed ID: 30868895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Jab1/Cops5: a promising target for cancer diagnosis and therapy.
    Yuan C; Wang D; Liu G; Pan Y
    Int J Clin Oncol; 2021 Jul; 26(7):1159-1169. PubMed ID: 34019195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAB1/COPS5 is a putative oncogene that controls critical oncoproteins deregulated in prostate cancer.
    Danielpour D; Purighalla S; Wang E; Zmina PM; Sarkar A; Zhou G
    Biochem Biophys Res Commun; 2019 Oct; 518(2):374-380. PubMed ID: 31434609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cytoplasmic shuttling and subsequent degradation of p27Kip1 mediated by Jab1/CSN5 and the COP9 signalosome complex.
    Tomoda K; Kubota Y; Arata Y; Mori S; Maeda M; Tanaka T; Yoshida M; Yoneda-Kato N; Kato JY
    J Biol Chem; 2002 Jan; 277(3):2302-10. PubMed ID: 11704659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Jab1/CSN5 mediates E2F dependent expression of mitotic and apoptotic but not DNA replication targets.
    Lu H; Liang X; Issaenko OA; Hallstrom TC
    Cell Cycle; 2011 Oct; 10(19):3317-26. PubMed ID: 21937878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer.
    Wang S; Oh DY; Leventaki V; Drakos E; Zhang R; Sahin AA; Resetkova E; Edgerton ME; Wu W; Claret FX
    Cancer Lett; 2019 Nov; 465():12-23. PubMed ID: 31473252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of Jab1/CSN5 induces radio- and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways.
    Pan Y; Zhang Q; Atsaves V; Yang H; Claret FX
    Oncogene; 2013 May; 32(22):2756-66. PubMed ID: 22797071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAB1/CSN5 and the COP9 signalosome. A complex situation.
    Chamovitz DA; Segal D
    EMBO Rep; 2001 Feb; 2(2):96-101. PubMed ID: 11258719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stat3 contributes to cancer progression by regulating Jab1/Csn5 expression.
    Pan Y; Wang S; Su B; Zhou F; Zhang R; Xu T; Zhang R; Leventaki V; Drakos E; Liu W; Claret FX
    Oncogene; 2017 Feb; 36(8):1069-1079. PubMed ID: 27524414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.